Repository logo
  • English
  • Deutsch
  • Español
  • Français
  • Log In
    New user? Click here to register.Have you forgotten your password?

  • English
  • Deutsch
  • Español
  • Français
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
  • Communities & Collections
  • Research Outputs
  • Fundings & Projects
  • Researchers
  • Statistics
  1. Home
  2. Current Research Information System UV
  3. Publicaciones
  4. Efficacy Of Systemic Oncological Treatments In Patients With Advanced Esophageal Or Gastric Cancers At High Risk Of Dying In The Middle And Short Term: An Overview Of Systematic Reviews
 
  • Details
Options

Efficacy Of Systemic Oncological Treatments In Patients With Advanced Esophageal Or Gastric Cancers At High Risk Of Dying In The Middle And Short Term: An Overview Of Systematic Reviews

Journal
BMC Cancer
Date Issued
2021-06-16
Author(s)
M. Santero
R. Acosta-Dighero
A. G. Meade
A. Antequera
A. Auladell-Rispau
M. J. Quintana
C. Requeijo
G. Rodríguez-Grijalva
K. Salas-Gama
R. Dorantes-Romandia
J. Salazar
I. Solà
G. Urrútia
X. Bonfill Cosp
Pérez, Javier  
Facultad de Medicina  
DOI
10.1186/s12885-021-08330-5
WoS ID
WOS:000664532200003
Abstract
Background: Esophageal and gastric cancers are a significant public health problem worldwide, with most patients presenting with advanced-stage disease and, consequently, poor prognosis. Systemic oncological treatments (SOT) have been widely used over more conservative approaches, such as supportive care. Nevertheless, its effectiveness in this scenario is not sufficiently clear. This paper provides an overview of systematic reviews that assessed the effectiveness of SOT compared with the best supportive care (BSC) or placebo in patients with advanced esophageal or gastric cancers in an end-of-life context. Methods: We searched MEDLINE, EMBASE, The Cochrane Library, Epistemonikos, and PROSPERO for eligible systematic reviews (SRs) published from 2008 onwards. The primary outcomes were overall survival (OS), progression-free survival (PFS), functional status, and toxicity. Two authors assessed eligibility and extracted data independently. We evaluated the methodological quality of included SRs using the AMSTAR-2 tool and the overlap of primary studies (corrected covered area, CCA). Also, we performed a de novo meta-analysis with data reported for each primary study when it was possible. We assessed the certainty of evidence using the GRADE approach. Results: We identified 16 SRs (19 included trials) for inclusion within this overview. Most reviews had a critically low methodological quality, and there was a very high overlap of primary studies. It is uncertain whether SOT improves OS and PFS over more conservative approaches due to the very low certainty of evidence. Conclusions: The evidence is very uncertain about the effectiveness of SOT for advanced esophageal or gastric cancers. High-quality SRs and further randomized clinical trials that include a thorough assessment of patient-centered outcomes are needed. Trial registration: Open Science Framework, https://doi.org/10.17605/OSF.IO/7CHX6.
Subjects

Cancer Research

Genetics

Oncology

OCDE Subjects

Medical And Health Sc...

Quartile (Date Issued)
Q2
License
acceso abierto
Open Science Path
https://creativecommons.org/licenses/by/4.0/

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback

Hosting & Support by

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science